About the partners

Malaria Consortium is the world's leading not-for-profit organisation dedicated to the control of malaria and applies its depth of technical expertise and practical experience to develop smarter solutions that improve and save lives. Through innovation, Malaria Consortium increases the impact of malaria and disease control programmes so that they benefit all communities, including delivery in the most challenging environments. Malaria Consortium has pioneered best practices and approaches, setting the standards that others now follow. Malaria Consortium is headquartered in London, United Kingdom, with over 90% of its staff based in malaria-endemic countries supporting Ministries of Health and partners in over twenty countries. For more information, please visit www.malariaconsortium.org.

An industry leader in almost every aspect of the energy and petrochemicals business, ExxonMobil operates facilities or markets products in most of the world's countries.

We engage in a range of philanthropic activities that advance education, health and science in the communities where we have significant operations.

In 2000, we established our Africa Health Initiative in support of the Abuja Declaration on Roll Back Malaria in Africa and its goal to halve malaria deaths by 2010. Since then, we have developed on-the-ground public-private partnerships to fight malaria at the community level, progress treatment and vaccine research, and raise awareness and international support.

Today, we have the most comprehensive malaria control programme of any oil and gas major in Africa, and are the largest non-pharmaceutical corporate donor to malaria research. As well as supporting new drug development, we are helping to distribute insecticide-treated bed nets to places where they are desperately needed.

To mark World Malaria Day, we announced an additional $1 million donation, bringing our commitment to organisations engaged in important community and social development projects in Africa to more than $150 million.

The Financial Times, one of the world's leading business news organisations, is recognised internationally for its authority, integrity and accuracy. Providing extensive news, comment and analysis, the newspaper is printed at 23 print sites across the globe, has a daily circulation of 412,854 (ABC figures, October, 2009) and a readership of 1.3 million people worldwide in print and online.

The FT ran a special malaria supplement around World Malaria Day 2009 which can be viewed at http://www.ft.com/reports/combating-malaria-2009

We have a challenging and inspiring mission: to improve the quality of human life by enabling people to do more, feel better and live longer. This mission gives us the purpose to develop innovative medicines and products that help millions of people around the world.

We are one of the few pharmaceutical companies researching both medicines and vaccines for the World Health Organization's three priority diseases - HIV/AIDS, tuberculosis and malaria, and are very proud to have developed some of the leading global medicines in these fields.

Despite the prevalence of malaria it can be prevented by controlling the breeding of mosquitoes and using low cost measures such as insecticide-treated nets (ITNs). Malaria can also be treated effectively using inexpensive drugs.

At GSK we are committed to playing a significant role in improving the health of communities affected by malaria in three ways:

• through on-going research into new malaria medicines, treatments and vaccines
• with preferential pricing of our anti-malarials in the least developed countries and sub-Saharan Africa
• through our community investment activities funded by the GSK African Malaria Partnership

Through its Malaria Initiative, Novartis provides Coartem, an efficacious high-quality antimalarial, without profit to over 45 malaria-endemic developing countries.

Since the start of the initiative in 2001, Novartis has supplied over 235 million Coartem treatments and helped save an estimated 600 000 lives.
Coartem has regulatory approval in over 80 countries including Switzerland and the United States. Recently, Novartis and Medicines for Malaria Venture developed a new easy-to-administer, sweet-tasting formulation, known as Coartem Dispersible for children -- the population group hardest hit by malaria. In the Novartis Institute for Tropical Diseases in Singapore, Novartis is leading research for the next generation of anti-malarial drugs to continue to save the lives of patients.

For more information, please visit http://www.novartis.com

Syngenta is one of the world's leading companies with more than 24,000 employees in over 90 countries. As a global supplier of vector control insecticides under the ICON and ACTELLIC brands, Syngenta works closely with many different partners to ensure that high quality and effective products for malaria prevention are available in the affected areas and supported by training in their safe and effective use. Syngenta's insecticide range leads the field in indoor residual spraying (IRS) - ICON 10CS - and long-lasting insecticide treatments for mosquito nets - ICON MAXX - both key components of an integrated strategy to prevent malaria transmission.

Vestergaard Frandsen is a leading innovator, manufacturer and exporter of complex emergency response and disease control textiles. It is guided by a unique Humanitarian Entrepreneurship business model, whose "profit for a purpose" approach has turned humanitarian responsibility into its core business.

Vestergaard Frandsen's PermaNet® is the world's best selling long-lasting insecticidal bed net, created to prevent the transmission of malaria. PermaNet® was first introduced in 2000, and an improved version called PermaNet® 2.0 was launched in 2003.

In December of 2008 Vestergaard Frandsen received World Health Organization interim recommendation for PermaNet® 3.0, the first bed net effective against insecticide resistant mosquitoes.

Vestergaard Frandsen will manufacture its 175 millionth PermaNet® bed net on World Malaria Day, April 25, 2009.

For more information about these products and about Vestergaard Frandsen, please visit our website www.vestergaard-frandsen.com